Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
01 Novembre 2023 - 12:00PM
Business Wire
Company management updates about ongoing
activities and progress
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncological and inflammatory diseases,
today confirmed that all of the Company’s clinical and business
development activities are ongoing and proceeding by both its
Israeli and US based staff.
“Can-Fite remains focused and stronger than ever in our purpose
to bring medications to market that improve and save lives. We are
working closely with our US based executives, Dr. Bill Kerns and
Dr. Michael Silverman, with all our consultants and our
collaboration partners in Canada, Europe, the US, China and South
Korea. All the investigators participating in the conductance of
the clinical studies are working full force and continue patient
enrolment for the ongoing advanced clinical studies,” stated Dr.
Pnina Fishman, Can-Fite’s Chief Scientific Officer and Executive
Chairman. “Our business development activities are robust and we
are receiving a high level of interest, in both Namodenoson and
Piclidenoson, which we believe may lead to new pharma partnerships
in the near-term.”
The Company’s advanced-stage clinical pipeline includes two
pivotal Phase III studies: an ongoing trial in advanced liver
cancer and a psoriasis study that has been cleared by the U.S. Food
and Drug Administration as well as the European Medicines Agency
and is expected to commence enrollment shortly. Phase II trials
include an ongoing study for steatotic liver disease (SLD),
formerly known as NASH, and preparatory work is underway for a
Phase IIa trial in pancreatic cancer.
Can-Fite’s latest value-driving developments include its entry
into the rare genetic diseases market with Piclidenoson which was
found to be effective in pre-clinical studies for the treatment of
Lowe Syndrome, an estimated $100 million treatment market in the
U.S. alone in which there is no therapeutic treatment option
available. Through a partnership with Collaborations
Pharmaceuticals, Can-Fite will now utilize artificial intelligence
(AI) and machine learning (ML) techniques to identify
next-generation A3 adenosine receptor drug agonists and
significantly reduce development time and costs of bringing such
drugs to market.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson recently reported
topline results in a Phase III trial for psoriasis and is expected
to commence a pivotal Phase III. Can-Fite's cancer and liver drug,
Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of steatotic liver disease (SLD), a Phase III pivotal
trial for hepatocellular carcinoma (HCC), and the Company is
planning a Phase IIa study in pancreatic cancer. Namodenoson has
been granted Orphan Drug Designation in the U.S. and Europe and
Fast Track Designation as a second line treatment for HCC by the
U.S. Food and Drug Administration. Namodenoson has also shown proof
of concept to potentially treat other cancers including colon,
prostate, and melanoma. CF602, the Company's third drug candidate,
has shown efficacy in the treatment of erectile dysfunction. These
drugs have an excellent safety profile with experience in over
1,600 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements This press release may contain
forward-looking statements, about Can-Fite’s expectations, beliefs
or intentions regarding, among other things, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. All statements in this
communication, other than those relating to historical facts, are
“forward looking statements”. Forward-looking statements can be
identified by the use of forward-looking words such as “believe,”
“expect,” “intend,” “plan,” “may,” “should” or “anticipate” or
their negatives or other variations of these words or other
comparable words or by the fact that these statements do not relate
strictly to historical or current matters. Forward-looking
statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and security, political and economic
instability in the Middle East that could harm our business,
including due to the current war between Israel and Hama. More
information on these risks, uncertainties and other factors is
included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101858156/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Grafico Azioni Can Fite BioPharma (AMEX:CANF)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Can Fite BioPharma (AMEX:CANF)
Storico
Da Set 2023 a Set 2024